{
    "xml": "<topic id=\"PHP538\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/infliximab\" basename=\"infliximab\" title=\"INFLIXIMAB\">\n<title>INFLIXIMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_991\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/infliximab\">Infliximab</xref>\n</p>\n<data name=\"vtmid\">108675009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_295286686\" title=\"Tumor necrosis factor alpha (TNF-a) inhibitors\">Tumor necrosis factor alpha (TNF-a) inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\r\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP63699\" outputclass=\"indicationsAndDose\" rev=\"1.44\" parent=\"/drugs/infliximab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe active Crohn's disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, then 5&#8239;mg/kg after 4&#8239;weeks, if condition has responded, then maintenance 5&#8239;mg/kg every 8&#8239;weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Fistulating Crohn's disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, if condition has responded consult product literature for guidance on further doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe active ulcerative colitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, then 5&#8239;mg/kg every 8&#8239;weeks, discontinue if no response 14 weeks after initial dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Rheumatoid arthritis (in combination with methotrexate)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 3&#8239;mg/kg, then 3&#8239;mg/kg after 2&#8239;weeks, followed by 3&#8239;mg/kg after 4&#8239;weeks, then 3&#8239;mg/kg every 8&#8239;weeks, dose to be increased only if response is inadequate after 12 weeks of initial treatment; increased in steps of 1.5&#8239;mg/kg every 8&#8239;weeks, increased if necessary up to 7.5&#8239;mg/kg every 8&#8239;weeks, alternatively increased if necessary to 3&#8239;mg/kg every 4&#8239;weeks, discontinue if no response by 12 weeks of initial infusion or after dose adjustment.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Ankylosing spondylitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, then 5&#8239;mg/kg every 6&#8211;8&#8239;weeks, discontinue if no response by 6 weeks of initial infusion.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Psoriatic arthritis (in combination with methotrexate)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, followed by 5&#8239;mg/kg every 8&#8239;weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Plaque psoriasis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, then 5&#8239;mg/kg every 8&#8239;weeks, discontinue if no response within 14 weeks of initial infusion.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63779\" outputclass=\"importantSafetyInformation\" rev=\"1.7\" parent=\"/drugs/infliximab\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Adequate resuscitation facilities must be available when infliximab is used.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63791\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/infliximab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Moderate or severe heart failure</ph>; <ph outputclass=\"contraindication\">severe infections</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63808\" outputclass=\"cautions\" rev=\"1.48\" parent=\"/drugs/infliximab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Demyelinating disorders (risk of exacerbation)</ph>; <ph outputclass=\"caution\">development of malignancy</ph>; <ph outputclass=\"caution\">hepatitis B virus&#8212;monitor for active infection</ph>; <ph outputclass=\"caution\">history of colon carcinoma (in inflammatory bowel disease)</ph>; <ph outputclass=\"caution\">history of dysplasia (in inflammatory bowel disease)</ph>; <ph outputclass=\"caution\">history of malignancy</ph>; <ph outputclass=\"caution\">history of prolonged immunosuppressant or PUVA treatment in patients with psoriasis</ph>; <ph outputclass=\"caution\">mild heart failure (discontinue if symptoms develop or worsen)</ph>; <ph outputclass=\"caution\">predisposition to infection (discontinue if new serious infection develops)</ph>; <ph outputclass=\"caution\">risk of delayed hypersensitivity reactions if drug-free interval exceeds 16 weeks</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Tuberculosis</p>\n<p>Active tuberculosis should be treated with standard treatment for at least 2 months before starting infliximab. Patients who have previously received adequate treatment for tuberculosis can start infliximab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting infliximab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with infliximab. </p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions </p>\n<p>Hypersensitivity reactions (including fever, chest pain, hypotension, hypertension, dyspnoea, transient visual loss, pruritus, urticaria, serum sickness-like reactions, angioedema, anaphylaxis) reported during or within 1&#8211;2 hours after infusion (risk greatest during first or second infusion or in patients who discontinue other immunosuppressants). Prophylactic antipyretics, antihistamines, or hydrocortisone may be administered.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63686\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/infliximab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (infliximab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63605\" outputclass=\"sideEffects\" rev=\"1.24\" parent=\"/drugs/infliximab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">ecchymosis</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal haemorrhage</ph>; <ph outputclass=\"sideEffect\">gastro-oesophageal reflux</ph>; <ph outputclass=\"sideEffect\">hyperhydrosis</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypoaesthesia</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">new onset or worsening psoriasis</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">sleep disturbances</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abnormal skin pigmentation</ph>; <ph outputclass=\"sideEffect\">agitation</ph>; <ph outputclass=\"sideEffect\">amnesia</ph>; <ph outputclass=\"sideEffect\">arrhythmia</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">bullous eruption</ph>; <ph outputclass=\"sideEffect\">cheilitis</ph>; <ph outputclass=\"sideEffect\">cholecystitis</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">eye disorders</ph>; <ph outputclass=\"sideEffect\">heart failure</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">hyperkeratosis</ph>; <ph outputclass=\"sideEffect\">impaired healing</ph>; <ph outputclass=\"sideEffect\">intestinal perforation</ph>; <ph outputclass=\"sideEffect\">nervousness</ph>; <ph outputclass=\"sideEffect\">neuropathy</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">peripheral ischaemia</ph>; <ph outputclass=\"sideEffect\">pleurisy</ph>; <ph outputclass=\"sideEffect\">pulmonary oedema</ph>; <ph outputclass=\"sideEffect\">rosacea</ph>; <ph outputclass=\"sideEffect\">seborrhoea</ph>; <ph outputclass=\"sideEffect\">seizures</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">vaginitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Demyelinating disorders</ph>; <ph outputclass=\"sideEffect\">interstitial lung disease</ph>; <ph outputclass=\"sideEffect\">leukaemia</ph>; <ph outputclass=\"sideEffect\">lymphoma</ph>; <ph outputclass=\"sideEffect\">pericardial effusion</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>; <ph outputclass=\"sideEffect\">vasospasm</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anaemia</ph>; <ph outputclass=\"sideEffect\">antibody formation</ph>; <ph outputclass=\"sideEffect\">aplastic anaemia</ph>; <ph outputclass=\"sideEffect\">blood disorders</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">hepatosplenic T-cell lymphoma (more likely in inflammatory bowel disease)</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">lupus erythematosus-like syndrome</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pancytopenia</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">worsening heart failure</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63800\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/infliximab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises adequate contraception during and for at least 6 months after last dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63680\" outputclass=\"pregnancy\" parent=\"/drugs/infliximab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63819\" outputclass=\"breastFeeding\" parent=\"/drugs/infliximab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Amount probably too small to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63633\" outputclass=\"preTreatmentScreening\" rev=\"1.9\" parent=\"/drugs/infliximab\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Tuberculosis</p>\n<p>Patients should be evaluated for tuberculosis before treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63464\" outputclass=\"monitoringRequirements\" parent=\"/drugs/infliximab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for infection before, during, and for 6 months after treatment.</p>\n<p>All patients should be observed carefully for 1&#8211;2 hours after infusion and resuscitation equipment should be available for immediate use (risk of hypersensitivity reactions).</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor for symptoms of delayed hypersensitivity if readministered after a prolonged period.</p>\n</sectiondiv>\n<sectiondiv>\n<p>When used for plaque psoriasis, monitor for non-melanoma skin cancer before and during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63837\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/infliximab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Remicade</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Sodium chloride 0.9%; reconstitute each 100-mg vial with 10&#8239;mL water for injections using a 21-gauge or smaller needle; gently swirl vial without shaking to dissolve; allow to stand for 5 minutes; dilute requisite dose with infusion fluid to a final volume of 250&#8239;mL and give through a low protein-binding filter (1.2&#8239;micron or less) over at least 2 hours (adults over 18 years who have tolerated 3 initial 2-hour infusions may be given subsequent infusions of up to 6&#8239;mg/kg over at least 1 hour); start infusion within 3 hours of reconstitution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63666\" outputclass=\"patientAndCarerAdvice\" rev=\"1.16\" parent=\"/drugs/infliximab\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>An alert card should be provided.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Tuberculosis</p>\n<p>Patients and carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Blood disorders</p>\n<p>Patients and carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Patients and carers should be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity develop.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63317\" outputclass=\"nationalFunding\" rev=\"1.48\" parent=\"/drugs/infliximab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA130</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)</p>\r\n<p>The tumour necrosis factor alpha (TNF-&#945;) inhibitor infliximab is an option for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-&#945; inhibitors should be given in combination with methotrexate.</p>\r\n<p>Infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-&#945; inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy.</p>\r\n<p>Use of TNF-&#945; inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA130\">www.nice.org.uk/TA130</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA134</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Infliximab for plaque psoriasis in adults (January 2008)</p>\r\n<p>Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA134\">www.nice.org.uk/TA134</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA143</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)</p>\r\n<p>Infliximab is not recommended for the treatment of ankylosing spondylitis. Patients who are already receiving infliximab for the treatment of ankylosing spondylitis can continue treatment until they and their specialist consider it appropriate to stop.</p>\r\n<p>See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA143\">www.nice.org.uk/TA143</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA163</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Infliximab for acute exacerbations of ulcerative colitis (December 2008)</p>\r\n<p>Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA163\">www.nice.org.uk/TA163</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA187</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Infliximab and adalimumab for Crohn&#8217;s disease (May 2010)</p>\r\n<p>Infliximab is recommended for the treatment of severe active Crohn&#8217;s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn&#8217;s disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications.</p>\r\n<p>Infliximab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease&#8212;in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, infliximab can be restarted.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA187\">www.nice.org.uk/TA187</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA195</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</p>\r\n<p>Infliximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA195\">www.nice.org.uk/TA195</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA199</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)</p>\r\n<p>Infliximab is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).</p>\r\n<p>Infliximab should be discontinued if there is an inadequate response at 12 weeks.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA199\">www.nice.org.uk/TA199</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA329</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)</p>\r\n<p>Infliximab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies.</p>\r\n<p>The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.</p>\r\n<p>Infliximab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA329\">www.nice.org.uk/TA329</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP538-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/infliximab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74642\" title=\"Powder for solution for infusion\" namespace=\"/drugs/infliximab/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"11\" rel=\"backlink\">Inflammatory bowel disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78375\" namespace=\"/treatment-summaries/eczema-and-psoriasis-drugs-affecting-the-immune-response\" title=\"Eczema and psoriasis, drugs affecting the immune response\" count=\"3\" rel=\"backlink\">Eczema and psoriasis, drugs affecting the immune response</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"3\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_991\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/infliximab\" title=\"Infliximab\" count=\"1\" rel=\"link\">Infliximab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74642\" namespace=\"/drugs/infliximab/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP538",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/infliximab",
    "basename": "infliximab",
    "title": "INFLIXIMAB",
    "interactants": [
        {
            "id": "bnf_int_991",
            "label": "Infliximab"
        }
    ],
    "vtmid": "108675009",
    "drugClassification": [
        "Tumor necrosis factor alpha (TNF-a) inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Severe active Crohn's disease",
                        "html": "Severe active Crohn's disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg/kg, then 5 mg/kg after 2 weeks, then 5 mg/kg after 4 weeks, if condition has responded, then maintenance 5 mg/kg every 8 weeks.",
                        "html": "<p>Initially 5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, then 5&#8239;mg/kg after 4&#8239;weeks, if condition has responded, then maintenance 5&#8239;mg/kg every 8&#8239;weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Fistulating Crohn's disease",
                        "html": "Fistulating Crohn's disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, if condition has responded consult product literature for guidance on further doses.",
                        "html": "<p>Initially 5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, if condition has responded consult product literature for guidance on further doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe active ulcerative colitis",
                        "html": "Severe active ulcerative colitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 8 weeks, discontinue if no response 14 weeks after initial dose.",
                        "html": "<p>Initially 5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, then 5&#8239;mg/kg every 8&#8239;weeks, discontinue if no response 14 weeks after initial dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Rheumatoid arthritis (in combination with methotrexate)",
                        "html": "Rheumatoid arthritis (in combination with methotrexate)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 3 mg/kg, then 3 mg/kg after 2 weeks, followed by 3 mg/kg after 4 weeks, then 3 mg/kg every 8 weeks, dose to be increased only if response is inadequate after 12 weeks of initial treatment; increased in steps of 1.5 mg/kg every 8 weeks, increased if necessary up to 7.5 mg/kg every 8 weeks, alternatively increased if necessary to 3 mg/kg every 4 weeks, discontinue if no response by 12 weeks of initial infusion or after dose adjustment.",
                        "html": "<p>Initially 3&#8239;mg/kg, then 3&#8239;mg/kg after 2&#8239;weeks, followed by 3&#8239;mg/kg after 4&#8239;weeks, then 3&#8239;mg/kg every 8&#8239;weeks, dose to be increased only if response is inadequate after 12 weeks of initial treatment; increased in steps of 1.5&#8239;mg/kg every 8&#8239;weeks, increased if necessary up to 7.5&#8239;mg/kg every 8&#8239;weeks, alternatively increased if necessary to 3&#8239;mg/kg every 4&#8239;weeks, discontinue if no response by 12 weeks of initial infusion or after dose adjustment.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Ankylosing spondylitis",
                        "html": "Ankylosing spondylitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 6&#8211;8 weeks, discontinue if no response by 6 weeks of initial infusion.",
                        "html": "<p>5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, then 5&#8239;mg/kg every 6&#8211;8&#8239;weeks, discontinue if no response by 6 weeks of initial infusion.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Psoriatic arthritis (in combination with methotrexate)",
                        "html": "Psoriatic arthritis (in combination with methotrexate)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, followed by 5 mg/kg every 8 weeks.",
                        "html": "<p>5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, followed by 5&#8239;mg/kg every 8&#8239;weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Plaque psoriasis",
                        "html": "Plaque psoriasis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 8 weeks, discontinue if no response within 14 weeks of initial infusion.",
                        "html": "<p>5&#8239;mg/kg, then 5&#8239;mg/kg after 2&#8239;weeks, followed by 5&#8239;mg/kg after 4&#8239;weeks, then 5&#8239;mg/kg every 8&#8239;weeks, discontinue if no response within 14 weeks of initial infusion.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "Adequate resuscitation facilities must be available when infliximab is used.",
                "html": "<p>Adequate resuscitation facilities must be available when infliximab is used.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Moderate or severe heart failure",
                "html": "Moderate or severe heart failure"
            },
            {
                "type": "contraindications",
                "textContent": "severe infections",
                "html": "severe infections"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Demyelinating disorders (risk of exacerbation)",
                "html": "Demyelinating disorders (risk of exacerbation)"
            },
            {
                "type": "cautions",
                "textContent": "development of malignancy",
                "html": "development of malignancy"
            },
            {
                "type": "cautions",
                "textContent": "hepatitis B virus&#8212;monitor for active infection",
                "html": "hepatitis B virus&#8212;monitor for active infection"
            },
            {
                "type": "cautions",
                "textContent": "history of colon carcinoma (in inflammatory bowel disease)",
                "html": "history of colon carcinoma (in inflammatory bowel disease)"
            },
            {
                "type": "cautions",
                "textContent": "history of dysplasia (in inflammatory bowel disease)",
                "html": "history of dysplasia (in inflammatory bowel disease)"
            },
            {
                "type": "cautions",
                "textContent": "history of malignancy",
                "html": "history of malignancy"
            },
            {
                "type": "cautions",
                "textContent": "history of prolonged immunosuppressant or PUVA treatment in patients with psoriasis",
                "html": "history of prolonged immunosuppressant or PUVA treatment in patients with psoriasis"
            },
            {
                "type": "cautions",
                "textContent": "mild heart failure (discontinue if symptoms develop or worsen)",
                "html": "mild heart failure (discontinue if symptoms develop or worsen)"
            },
            {
                "type": "cautions",
                "textContent": "predisposition to infection (discontinue if new serious infection develops)",
                "html": "predisposition to infection (discontinue if new serious infection develops)"
            },
            {
                "type": "cautions",
                "textContent": "risk of delayed hypersensitivity reactions if drug-free interval exceeds 16 weeks",
                "html": "risk of delayed hypersensitivity reactions if drug-free interval exceeds 16 weeks"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Tuberculosis",
                "textContent": "Active tuberculosis should be treated with standard treatment for at least 2 months before starting infliximab. Patients who have previously received adequate treatment for tuberculosis can start infliximab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting infliximab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with infliximab.",
                "html": "<p>Active tuberculosis should be treated with standard treatment for at least 2 months before starting infliximab. Patients who have previously received adequate treatment for tuberculosis can start infliximab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting infliximab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with infliximab. </p>"
            },
            {
                "type": "importantAdvice",
                "title": "Hypersensitivity reactions",
                "textContent": "Hypersensitivity reactions (including fever, chest pain, hypotension, hypertension, dyspnoea, transient visual loss, pruritus, urticaria, serum sickness-like reactions, angioedema, anaphylaxis) reported during or within 1&#8211;2 hours after infusion (risk greatest during first or second infusion or in patients who discontinue other immunosuppressants). Prophylactic antipyretics, antihistamines, or hydrocortisone may be administered.",
                "html": "<p>Hypersensitivity reactions (including fever, chest pain, hypotension, hypertension, dyspnoea, transient visual loss, pruritus, urticaria, serum sickness-like reactions, angioedema, anaphylaxis) reported during or within 1&#8211;2 hours after infusion (risk greatest during first or second infusion or in patients who discontinue other immunosuppressants). Prophylactic antipyretics, antihistamines, or hydrocortisone may be administered.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (infliximab).",
                "html": "<p>Appendix 1 (infliximab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "ecchymosis",
                        "html": "ecchymosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-intestinal haemorrhage",
                        "html": "gastro-intestinal haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastro-oesophageal reflux",
                        "html": "gastro-oesophageal reflux",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperhydrosis",
                        "html": "hyperhydrosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypoaesthesia",
                        "html": "hypoaesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "new onset or worsening psoriasis",
                        "html": "new onset or worsening psoriasis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sleep disturbances",
                        "html": "sleep disturbances",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Abnormal skin pigmentation",
                        "html": "Abnormal skin pigmentation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "agitation",
                        "html": "agitation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "amnesia",
                        "html": "amnesia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "arrhythmia",
                        "html": "arrhythmia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bullous eruption",
                        "html": "bullous eruption",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cheilitis",
                        "html": "cheilitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "cholecystitis",
                        "html": "cholecystitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "eye disorders",
                        "html": "eye disorders",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "heart failure",
                        "html": "heart failure",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hyperkeratosis",
                        "html": "hyperkeratosis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "impaired healing",
                        "html": "impaired healing",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "intestinal perforation",
                        "html": "intestinal perforation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "nervousness",
                        "html": "nervousness",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "neuropathy",
                        "html": "neuropathy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "peripheral ischaemia",
                        "html": "peripheral ischaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pleurisy",
                        "html": "pleurisy",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pulmonary oedema",
                        "html": "pulmonary oedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rosacea",
                        "html": "rosacea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "seborrhoea",
                        "html": "seborrhoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "seizures",
                        "html": "seizures",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vaginitis",
                        "html": "vaginitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Demyelinating disorders",
                        "html": "Demyelinating disorders",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "interstitial lung disease",
                        "html": "interstitial lung disease",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "leukaemia",
                        "html": "leukaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "lymphoma",
                        "html": "lymphoma",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pericardial effusion",
                        "html": "pericardial effusion",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "vasospasm",
                        "html": "vasospasm",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anaemia",
                        "html": "anaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "antibody formation",
                        "html": "antibody formation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "aplastic anaemia",
                        "html": "aplastic anaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "blood disorders",
                        "html": "blood disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatosplenic T-cell lymphoma (more likely in inflammatory bowel disease)",
                        "html": "hepatosplenic T-cell lymphoma (more likely in inflammatory bowel disease)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lupus erythematosus-like syndrome",
                        "html": "lupus erythematosus-like syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pancytopenia",
                        "html": "pancytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "worsening heart failure",
                        "html": "worsening heart failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.",
                "html": "<p>Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises adequate contraception during and for at least 6 months after last dose.",
                "html": "<p>Manufacturer advises adequate contraception during and for at least 6 months after last dose.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if essential.",
                "html": "<p>Use only if essential.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Amount probably too small to be harmful.",
                "html": "<p>Amount probably too small to be harmful.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "title": "Tuberculosis",
                "textContent": "Patients should be evaluated for tuberculosis before treatment.",
                "html": "<p>Patients should be evaluated for tuberculosis before treatment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for infection before, during, and for 6 months after treatment.\n\nAll patients should be observed carefully for 1&#8211;2 hours after infusion and resuscitation equipment should be available for immediate use (risk of hypersensitivity reactions).",
                "html": "<p>Monitor for infection before, during, and for 6 months after treatment.</p><p>All patients should be observed carefully for 1&#8211;2 hours after infusion and resuscitation equipment should be available for immediate use (risk of hypersensitivity reactions).</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor for symptoms of delayed hypersensitivity if readministered after a prolonged period.",
                "html": "<p>Monitor for symptoms of delayed hypersensitivity if readministered after a prolonged period.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "When used for plaque psoriasis, monitor for non-melanoma skin cancer before and during treatment.",
                "html": "<p>When used for plaque psoriasis, monitor for non-melanoma skin cancer before and during treatment.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Remicade ), give intermittently in Sodium chloride 0.9%; reconstitute each 100-mg vial with 10 mL water for injections using a 21-gauge or smaller needle; gently swirl vial without shaking to dissolve; allow to stand for 5 minutes; dilute requisite dose with infusion fluid to a final volume of 250 mL and give through a low protein-binding filter (1.2 micron or less) over at least 2 hours (adults over 18 years who have tolerated 3 initial 2-hour infusions may be given subsequent infusions of up to 6 mg/kg over at least 1 hour); start infusion within 3 hours of reconstitution.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Remicade</i>\n<tm tmtype=\"reg\"/>), give intermittently <i>in</i> Sodium chloride 0.9%; reconstitute each 100-mg vial with 10&#8239;mL water for injections using a 21-gauge or smaller needle; gently swirl vial without shaking to dissolve; allow to stand for 5 minutes; dilute requisite dose with infusion fluid to a final volume of 250&#8239;mL and give through a low protein-binding filter (1.2&#8239;micron or less) over at least 2 hours (adults over 18 years who have tolerated 3 initial 2-hour infusions may be given subsequent infusions of up to 6&#8239;mg/kg over at least 1 hour); start infusion within 3 hours of reconstitution.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "An alert card should be provided.",
                "html": "<p>An alert card should be provided.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Tuberculosis",
                "textContent": "Patients and carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.",
                "html": "<p>Patients and carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Blood disorders",
                "textContent": "Patients and carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.",
                "html": "<p>Patients and carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Hypersensitivity reactions",
                "textContent": "Patients and carers should be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity develop.",
                "html": "<p>Patients and carers should be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity develop.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA130",
                        "label": "www.nice.org.uk/TA130"
                    }
                ],
                "fundingIdentifier": "NICE TA130",
                "textContent": "Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007) The tumour necrosis factor alpha (TNF-&#945;) inhibitor infliximab is an option for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-&#945; inhibitors should be given in combination with methotrexate. Infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-&#945; inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy. Use of TNF-&#945; inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.\n\nwww.nice.org.uk/TA130",
                "html": "<p outputclass=\"title\">Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)</p> <p>The tumour necrosis factor alpha (TNF-&#945;) inhibitor infliximab is an option for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-&#945; inhibitors should be given in combination with methotrexate.</p> <p>Infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-&#945; inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy.</p> <p>Use of TNF-&#945; inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA130\">www.nice.org.uk/TA130</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA134",
                        "label": "www.nice.org.uk/TA134"
                    }
                ],
                "fundingIdentifier": "NICE TA134",
                "textContent": "Infliximab for plaque psoriasis in adults (January 2008) Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.\n\nwww.nice.org.uk/TA134",
                "html": "<p outputclass=\"title\">Infliximab for plaque psoriasis in adults (January 2008)</p> <p>Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA134\">www.nice.org.uk/TA134</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA143",
                        "label": "www.nice.org.uk/TA143"
                    }
                ],
                "fundingIdentifier": "NICE TA143",
                "textContent": "Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008) Infliximab is not recommended for the treatment of ankylosing spondylitis. Patients who are already receiving infliximab for the treatment of ankylosing spondylitis can continue treatment until they and their specialist consider it appropriate to stop. See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment.\n\nwww.nice.org.uk/TA143",
                "html": "<p outputclass=\"title\">Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)</p> <p>Infliximab is not recommended for the treatment of ankylosing spondylitis. Patients who are already receiving infliximab for the treatment of ankylosing spondylitis can continue treatment until they and their specialist consider it appropriate to stop.</p> <p>See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA143\">www.nice.org.uk/TA143</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA163",
                        "label": "www.nice.org.uk/TA163"
                    }
                ],
                "fundingIdentifier": "NICE TA163",
                "textContent": "Infliximab for acute exacerbations of ulcerative colitis (December 2008) Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate.\n\nwww.nice.org.uk/TA163",
                "html": "<p outputclass=\"title\">Infliximab for acute exacerbations of ulcerative colitis (December 2008)</p> <p>Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA163\">www.nice.org.uk/TA163</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA187",
                        "label": "www.nice.org.uk/TA187"
                    }
                ],
                "fundingIdentifier": "NICE TA187",
                "textContent": "Infliximab and adalimumab for Crohn&#8217;s disease (May 2010) Infliximab is recommended for the treatment of severe active Crohn&#8217;s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn&#8217;s disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications. Infliximab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease&#8212;in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, infliximab can be restarted.\n\nwww.nice.org.uk/TA187",
                "html": "<p outputclass=\"title\">Infliximab and adalimumab for Crohn&#8217;s disease (May 2010)</p> <p>Infliximab is recommended for the treatment of severe active Crohn&#8217;s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn&#8217;s disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications.</p> <p>Infliximab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease&#8212;in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, infliximab can be restarted.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA187\">www.nice.org.uk/TA187</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA195",
                        "label": "www.nice.org.uk/TA195"
                    }
                ],
                "fundingIdentifier": "NICE TA195",
                "textContent": "Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) Infliximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.\n\nwww.nice.org.uk/TA195",
                "html": "<p outputclass=\"title\">Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)</p> <p>Infliximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA195\">www.nice.org.uk/TA195</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA199",
                        "label": "www.nice.org.uk/TA199"
                    }
                ],
                "fundingIdentifier": "NICE TA199",
                "textContent": "Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010) Infliximab is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination). Infliximab should be discontinued if there is an inadequate response at 12 weeks.\n\nwww.nice.org.uk/TA199",
                "html": "<p outputclass=\"title\">Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)</p> <p>Infliximab is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).</p> <p>Infliximab should be discontinued if there is an inadequate response at 12 weeks.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA199\">www.nice.org.uk/TA199</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA329",
                        "label": "www.nice.org.uk/TA329"
                    }
                ],
                "fundingIdentifier": "NICE TA329",
                "textContent": "Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) Infliximab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies. The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen. Infliximab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.\n\nwww.nice.org.uk/TA329",
                "html": "<p outputclass=\"title\">Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)</p> <p>Infliximab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies.</p> <p>The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.</p> <p>Infliximab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA329\">www.nice.org.uk/TA329</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74642",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78375",
                "label": "Eczema and psoriasis, drugs affecting the immune response",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_991",
                "label": "Infliximab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74642",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}